Skip to main content
Erschienen in: BMC Cancer 1/2014

Open Access 01.12.2014 | Erratum

Erratum To: UCN-01 induces S and G2/M cell cycle arrest through the p53/p21waf1 or CHK2/CDC25C pathways and can suppress invasion in human hepatoma cell lines

verfasst von: Guoyi Wu, Linan Xu, Nan Lin, Bo Liu, Mark A Feitelson

Erschienen in: BMC Cancer | Ausgabe 1/2014

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
The online version of the original article can be found at 10.​1186/​1471-2407-13-167
Guoyi Wu, Linan Xu contributed equally to this work.

Correction

After publication of this work [1], we noted that we inadvertently failed to include the complete list of all co-authors. In addition, it has been brought to our attention that an Authors Contributions section was not included in the published article. In this correction we rectify these mistakes. The full list of authors and the Authors Contributions section are reported below and the Acknowledgements section has been modified accordingly. We apologize for any inconvenience this oversight may have caused.

Corrected Authors’ List

Guoyi Wu(1), Nan Lin(2), Linan Xu(3), Bo Liu(1) and Mark A. Feitelson(4)
1 Department of General Surgery, the lingnan Hospital, the Third Affiliated Hospital, Sun Yat-Sen University, GuangZhou 510630, PR China
2 Department of Hepatobiliary Surgery, the Third Affiliated Hospital, Sun Yat-Sen University, GuangZhou, 510630, PR China
3 Department of Gynecology and Obstetrics, the First Affiliated Hospital, Sun Yat-Sen University, GuangZhou 510089, PR China
4 Department of Biology, College of Science and Technology, Temple University, Philadelphia, PA 19122 USA

Corrected Acknowledgements

This research is supported by National Science Foundation of China (81272642), the National Science Foundation for Young Scholars of China (81000674), Fundamental research funds for the central universities (10120110040) and Natural Science Foundation of Guangdong Province, China (S2011010004729). This work was also supported by the NIH grants AI076535 and CA104025 to MF.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
The Creative Commons Public Domain Dedication waiver (https://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
download
DOWNLOAD
print
DRUCKEN
Metadaten
Titel
Erratum To: UCN-01 induces S and G2/M cell cycle arrest through the p53/p21waf1 or CHK2/CDC25C pathways and can suppress invasion in human hepatoma cell lines
verfasst von
Guoyi Wu
Linan Xu
Nan Lin
Bo Liu
Mark A Feitelson
Publikationsdatum
01.12.2014
Verlag
BioMed Central
Erschienen in
BMC Cancer / Ausgabe 1/2014
Elektronische ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-216

Weitere Artikel der Ausgabe 1/2014

BMC Cancer 1/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.